Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.
Approximately 60% of newly diagnosed rectal cancers are locally advanced. The standard of care for these malignancies is treating with DNA-damaging agents, neoadjuvant chemoradiation therapy (nCRT) or radiation, followed by surgery. Unfortunately, 70-80% of patients experience less than a complete response, but are not spared the toxicity of CRT. At present, there is no clinically actionable biomarker to predict which patients are likely to respond to nCRT. A biomarker of nCRT response will allow precision treatment, leading to improved clinical outcomes.
Researchers from Fox Chase Cancer Center developed a new technology to detect therapeutic response in rectal cancers, based on solid science as follows. Patients with poor DNA damage repair mechanisms have a more favorable response to DNA damaging treatments. Gamma-H2AX (γH2AX) is a phosphorylated H2AX histone that is used as a marker of DNA double stand breaks and cellular response to DNA damage. The study aimed to determine whether differences in the γH2AX levels of pre-treatment peripheral blood lymphocytes (PBLs) of rectal cancer patients were predictive of their response to nCRT. The data showed that rectal cancer patients who differ in their response to nCRT also differ in DNA-Damage Recognition and Repair (DRR) capacity, suggesting that DNA-DRR capacity can form the basis of a biomarker. As γ-H2AX and other DNA-DRR biomarkers were evaluated in pPBLs (germline DNA), the latter, either treatment-naïve or post-treatment, can be used for the analyses.
International patent application has been published (WO 2018/152154 A1)
For Partnering/Licensing information, please contact:
Inna Khartchenko, MS, MBA
Director, Technology Transfer and New Ventures
Inna.Khartchenko@fccc.edu